Nadler L M, Reinherz E L, Weinstein H J, D'Orsi C J, Schlossman S F
Blood. 1980 May;55(5):806-10.
To determine the T-cell lineage of the malignant lymphoblast in lymphoblastic lymphoma, tumor cells from nine patients were phenotyped employing a T-cell subset specific heteroantisera, TH2. The normal human peripheral blood T-cell compartment is composed of 80% TH2-negative and 20% TH2-positive T cells, as defined by reactivity with subset specific heteroantisera. Human suppressor cells are TH2 reactive, whereas helper cells are TH2 unreactive. Tumor cells from the majority of patients with lymphoblastic lymphoma were TH2 reactive in contrast to the lack of reactivity previously described in the majority of patients with T-cell acute lymphoblastic leukemia. Comparative clinical studies, including disease presentation and course, were correlated with the presence of the TH2 antigen on the tumor cell. These results provide evidence to support the notion of heterogeneity in the T-lymphoblastic malignancies and suggest that lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia are probably not a single disease process.
为了确定淋巴细胞性淋巴瘤中恶性淋巴母细胞的T细胞谱系,使用T细胞亚群特异性异种抗血清TH2对9例患者的肿瘤细胞进行了表型分析。根据与亚群特异性异种抗血清的反应性定义,正常人外周血T细胞区室由80%的TH2阴性T细胞和20%的TH2阳性T细胞组成。人类抑制细胞对TH2有反应,而辅助细胞对TH2无反应。与大多数T细胞急性淋巴细胞白血病患者中先前描述的无反应性相反,大多数淋巴细胞性淋巴瘤患者的肿瘤细胞对TH2有反应。包括疾病表现和病程在内的比较临床研究与肿瘤细胞上TH2抗原的存在相关。这些结果为支持T淋巴细胞恶性肿瘤异质性的观点提供了证据,并表明淋巴细胞性淋巴瘤和T细胞急性淋巴细胞白血病可能不是单一的疾病过程。